Dana-Farber Cancer Institute

This is your central portal for breaking news, the latest research and important updates from Dana-Farber Cancer Institute. Bookmark this page and check back often for updates.

Meeting NewsPerspective

Novel blood tests could improve cancer detection

November 14, 2019
Two novel blood assays demonstrated efficacy in detecting various cancer types at different disease stages, according to results of two studies…
In the Journals

Pembrolizumab induces durable responses in relapsed, refractory primary mediastinal large B-cell lymphoma

November 14, 2019
Pembrolizumab appeared to be associated with high response rates, durable activity and manageable toxicity among patients with relapsed or refractory…

Trial of KD025 for chronic GVHD meets primary endpoint at interim analysis

November 12, 2019
A pivotal trial designed to assess KD025 for patients with pretreated chronic graft-versus-host disease met its primary endpoint of overall response…
Meeting News

Researchers to be honored at San Antonio Breast Cancer Symposium

October 31, 2019
The San Antonio Breast Cancer Symposium and American Association for Cancer Research — one of the conference’s co-sponsors — will…

Hematologists, oncologists elected to National Academy of Medicine

October 30, 2019
The National Academy of Medicine announced the election of 90 regular members and 10 international members. Election to the academy —…
In the Journals

Nivolumab-bevacizumab combination safe, active in relapsed ovarian cancer

October 11, 2019
A combination of nivolumab and bevacizumab appeared safe and induced responses among women with relapsed ovarian cancer, according to results of a…
Feature

Program takes ‘stepped-care’ approach to curing cancer survivors of insomnia

October 11, 2019
The importance of good sleep habits has been reinforced by research and become well-known among the general public. Insufficient sleep has been…

The Leukemia & Lymphoma Society awards $13.8 million for research into pediatric blood cancers

October 9, 2019
The Leukemia & Lymphoma Society awarded $13.8 million in new pediatric research grants designed to identify more effective and precise treatments…

Researchers share Nobel Prize for discoveries that may improve treatment of cancer, anemia

October 7, 2019
Three scientists — two from the United States and one from England — the Nobel Prize in Medicine or Physiology for their discoveries of…
In the Journals

Avelumab active in mismatch repair-deficient endometrial cancer

October 3, 2019
Avelumab induced promising activity among women with mismatch repair-deficient endometrial cancer regardless of PD-L1 status, according to results of…
Meeting News

Addition of M6620 to gemcitabine prolongs PFS in platinum-resistant ovarian cancer

September 29, 2019
BARCELONA, Spain — The addition of the ATR kinase inhibitor M6620 to gemcitabine extended PFS without additional toxicity among patients with…
In the Journals

Stress ‘primary driver’ for fatigue in patients with SLE

September 12, 2019
Although depression and stress are both predictors of fatigue among patients with systemic lupus erythematosus at 1 year, stress is the…
In the Journals

Exercise linked to longer PFS, fewer treatment-related toxicities in metastatic colorectal cancer

August 21, 2019
Patients with metastatic colorectal cancer who exercised regularly achieved longer PFS than those who did not, according to results of a companion…

American Society for Radiation Oncology members receive fellow designation

August 8, 2019
American Society for Radiation Oncology designated 26 members to receive ASTRO fellow designation. The honorees will be recognized during the…

The University of Texas MD Anderson Cancer Center ranked best cancer hospital in nation

July 30, 2019
The University of Texas MD Anderson Cancer Center has retained its distinction as the No. 1 cancer hospital in the country. MD Anderson tops U.S
Meeting News

HemOnc Today honors Next Gen Innovators

HemOnc Today, July 25, 2019
HemOnc Today held a reception at ASCO Annual Meeting to honor its third class of Next Gen Innovators. The publication’s 111 Next Gen…
Point/Counter

Should lenvatinib be used as first-line therapy for slowly progressing radioiodine-refractory thyroid carcinoma?

HemOnc Today, July 10, 2019
POINT Lenvatinib is my preference as a first-line therapy when patients need treatment beyond levothyroxine and thyroid-stimulating hormone suppression.
Meeting NewsVideo

VIDEO: Tumor size, node status, age affect risk for breast cancer mortality

July 10, 2019
CHICAGO — At the ASCO Annual Meeting, Jose Pablo Leone, MD, medical oncologist at Dana-Farber Cancer Institute, spoke with HemOnc Today
Meeting NewsVideo

VIDEO: Eribulin plus pembrolizumab shows no clinical benefit in breast cancer subtype

July 2, 2019
CHICAGO — The addition of pembrolizumab to eribulin demonstrated no significant improvements in terms of PFS, OS or objective response rate…
In the Journals

High cardiac radiation dose may increase mortality odds in patients with lung cancer

July 2, 2019
Among patients with non-small cell lung cancer, a higher cardiac radiation dose may lead to elevated risk for major adverse cardiac events and…